ImmunityBio, Inc.
Financials
Valuation Metrics
ImmunityBio, Inc.'s Market Cap is $8.88B. At end of 2025 it was $1.96B. Ranked #1000 of 3,121 in US market (top 32%), #322 of 1,463 on NASDAQ (top 22%), #51 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.88B | US#1,000/3,121 Sec#51/266 |
| Revenue | $166M | US#2,615/3,121 Sec#115/266 |
| Net Income | $-992M | US—/3,121 Sec—/266 |
| Total Assets | $629M | US#2,684/3,121 Sec#140/266 |
| Net Assets | $-1.05B | US#3,047/3,121 Sec#265/266 |
| Employees | 688 | US#2,143/3,121 Sec#70/266 |
| Value | ||
| P/S | 53.57x | US#2,918/3,121 Sec#164/266 |
| FCF Yield | -4.12% | US—/3,121 Sec—/266 |
| Profitability | ||
| Op. Margin | -151.88% | US#2,761/3,121 Sec#131/266 |
| Revenue Growth | 192.92% | US#56/3,121 Sec#22/266 |
| Financial Health | ||
| Total Debt | $813M | US#1,649/3,121 Sec#48/266 |
| FCF | $-366M | US#2,875/3,121 Sec#244/266 |
| Cash | $76M | US#2,378/3,121 Sec#197/266 |
| Current Ratio | 5.72x | US#413/3,121 Sec#130/266 |
| Performance | ||
| 1Y Return | 197.54% | US#66/3,121 Sec#24/266 |
| 1M Return | 4.31% | US#254/3,121 Sec#29/266 |
| From 52W High | -31.78% | US#2,155/3,121 Sec#170/266 |
| 1Y MDD | -42.34% | US#2,131/3,121 Sec#150/266 |
| Trading | ||
| Volume | 14,880,762 shares | US#77/3,121 Sec#4/266 |
| Trading Value | $125M | US#578/3,121 Sec#36/266 |
| Per Share | ||
| EPS | $-0.95 | US—/3,121 Sec—/266 |
| BPS | $-1.00 | US—/3,121 Sec—/266 |
Company Info
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.